Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon575 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00267 | 35160204 | J Clin Med | Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. | 2022 | Details |
| A00303 | 35144334 | Endocrinol Metab (Seoul) | Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway. | 2022 | Details |
| A00318 | 35140289 | Sci Rep | Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. | 2022 | Details |
| A00324 | 35134508 | J Nutr Biochem | Mechanisms of autophagic responses to altered nutritional status. | 2022 | Details |
| A00391 | 35104330 | Diabetes Care | Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. | 2022 | Details |
| A00394 | 35102183 | Sci Rep | Intergenerational effects of preconception opioids on glucose homeostasis and hepatic transcription in adult male rats. | 2022 | Details |
| A00446 | 35080048 | J Gastroenterol Hepatol | Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A00447 | 35079935 | Mol Biol Rep | Physiological significance of bistable circuit design in metabolic homeostasis: role of integrated insulin-glucagon signalling network. | 2022 | Details |
| A00474 | 35068796 | J Clin Exp Hepatol | A Current Understanding of Bile Acids in Chronic Liver Disease. | 2021 | Details |
| A00475 | 35068786 | J Clin Exp Hepatol | Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. | 2021 | Details |
| A00482 | 35066087 | J Hepatol | Is it time for chronopharmacology in NASH? | 2022 | Details |
| A00516 | 35054924 | Int J Mol Sci | GLP-1a: Going beyond Traditional Use. | 2022 | Details |
| A00521 | 35053962 | Foods | Limosilactobacillus fermentum MG4295 Improves Hyperglycemia in High-Fat Diet-Induced Mice. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00616 | 35027111 | J Am Coll Cardiol | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. | 2022 | Details |
| A00651 | 35014161 | Diabetes Obes Metab | The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. | 2022 | Details |
| A00724 | 34988690 | Acta Diabetol | Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. | 2022 | Details |
| A00826 | 34956080 | Front Endocrinol (Lausanne) | Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A00851 | 34948020 | Int J Mol Sci | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00856 | 34945051 | J Clin Med | Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. | 2021 | Details |
| A00901 | 34934197 | Acta Pharmacol Sin | GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. | 2021 | Details |
| A00971 | 34915054 | J Hepatol | A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. | 2021 | Details |
| A01065 | 34882949 | Diabetes Obes Metab | Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. | 2022 | Details |
| A01097 | 34870138 | Metabol Open | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). | 2021 | Details |
| A01098 | 34869957 | JACC Basic Transl Sci | Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. | 2021 | Details |
| A01147 | 34855339 | FP Essent | Liver Disease: Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01215 | 34827579 | Biomolecules | Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms. | 2021 | Details |
| A01218 | 34825156 | JHEP Rep | Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. | 2021 | Details |
| A01277 | 34805029 | Can J Gastroenterol Hepatol | GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. | 2021 | Details |
| A01368 | 34773257 | Hepatology | A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. | 2021 | Details |
| A01387 | 34764398 | Sci Rep | A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). | 2021 | Details |
| A01562 | 34693236 | JHEP Rep | Non-alcoholic fatty liver disease: A patient guideline. | 2021 | Details |
| A01741 | 34630909 | World J Diabetes | Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. | 2021 | Details |
| A01761 | 34627692 | Nutr Metab Cardiovasc Dis | Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. | 2021 | Details |
| A01811 | 34606980 | Endocr Pract | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A01894 | 34570916 | Aliment Pharmacol Ther | Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. | 2021 | Details |
| A01937 | 34558835 | Hepatol Commun | Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. | 2021 | Details |
| A01948 | 34557367 | Cureus | Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. | 2021 | Details |
| A01961 | 34552561 | Front Endocrinol (Lausanne) | GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. | 2021 | Details |
| A02002 | 34533632 | J Gastroenterol | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. | 2021 | Details |
| A02004 | 34533266 | Hepatol Res | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. | 2021 | Details |
| A02194 | 34465857 | Int J Obes (Lond) | Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. | 2021 | Details |
| A02296 | 34433051 | Cell Rep | Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria. | 2021 | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | 2021 | Details |
| A02349 | 34406410 | J Clin Endocrinol Metab | The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. | 2022 | Details |
| A02363 | 34402473 | Eur J Gastroenterol Hepatol | Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. | 2021 | Details |
| A02418 | 34381196 | Nat Rev Endocrinol | GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. | 2021 | Details |
| A02436 | 34371959 | Nutrients | Whey Protein Supplementation Improves the Glycemic Response and May Reduce Non-Alcoholic Fatty Liver Disease Related Biomarkers in Women with Polycystic Ovary Syndrome (PCOS). | 2021 | Details |
| A02485 | 34357836 | Curr Med Res Opin | Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity. | 2021 | Details |
| A02521 | 34342168 | Physiol Rep | Hormonal regulation of glycine decarboxylase and its relationship to oxidative stress. | 2021 | Details |
| A02574 | 34326020 | Surg Obes Relat Dis | Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. | 2021 | Details |
| A02674 | 34289506 | Semin Liver Dis | Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. | 2021 | Details |
| A02709 | 34276380 | Front Pharmacol | Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1. | 2021 | Details |
| A02857 | 34214406 | Expert Opin Investig Drugs | Anti-diabetic drugs and NASH: from current options to promising perspectives. | 2021 | Details |
| A02870 | 34211180 | Nat Metab | Intestinal MYC modulates obesity-related metabolic dysfunction. | 2021 | Details |
| A02961 | 34183709 | Sci Rep | The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. | 2021 | Details |
| A03013 | 34164242 | Cureus | Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. | 2021 | Details |
| A03040 | 34155798 | Liver Int | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? | 2021 | Details |
| A03076 | 34139927 | Pharm Biol | Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) via restoring the balance of intestinal flora in rats. | 2021 | Details |
| A03104 | 34129693 | Hepatology | Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. | 2021 | Details |
| A03159 | 34107584 | Zhonghua Gan Zang Bing Za Zhi | [Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver]. | 2021 | Details |
| A03163 | 34106786 | Am J Physiol Cell Physiol | Impaired Ca2+ signaling due to hepatic steatosis mediates hepatic insulin resistance in Alström syndrome mice that is reversed by GLP-1 analog treatment. | 2021 | Details |
| A03232 | 34078383 | J Transl Med | Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. | 2021 | Details |
| A03289 | 34059612 | Curr Opin Cardiol | Update on cardiovascular risk in nonalcoholic fatty liver disease. | 2021 | Details |
| A03310 | 34049870 | BMJ Open Diabetes Res Care | Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes. | 2021 | Details |
| A03385 | 34022222 | J Biol Chem | Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. | 2021 | Details |
| A03561 | 33953700 | Front Endocrinol (Lausanne) | Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway. | 2021 | Details |
| A03600 | 33937257 | Front Cell Dev Biol | Autophagy in Hepatic Steatosis: A Structured Review. | 2021 | Details |
| A03704 | 33897616 | Front Endocrinol (Lausanne) | Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. | 2021 | Details |
| A03843 | 33851458 | Hepatology | Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. | 2021 | Details |
| A03858 | 33844015 | Toxicol Sci | Perfluorooctanesulfonic Acid (PFOS) Thwarts the Beneficial Effects of Calorie Restriction and Metformin. | 2021 | Details |
| A04128 | 33746742 | Front Pharmacol | Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway. | 2021 | Details |
| A04147 | 33741532 | Mol Metab | TCF7 is not essential for glucose homeostasis in mice. | 2021 | Details |
| A04170 | 33729777 | J Agric Food Chem | Dietary Polyphenols to Combat Nonalcoholic Fatty Liver Disease via the Gut-Brain-Liver Axis: A Review of Possible Mechanisms. | 2021 | Details |
| A04327 | 33664710 | Front Endocrinol (Lausanne) | Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. | 2021 | Details |
| A04349 | 33652942 | Int J Mol Sci | Treatments for NAFLD: State of Art. | 2021 | Details |
| A04418 | 33626072 | PLoS One | Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. | 2021 | Details |
| A04674 | 33545428 | Cell Mol Gastroenterol Hepatol | SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04739 | 33520110 | World J Diabetes | Novel glucose-lowering drugs for non-alcoholic fatty liver disease. | 2021 | Details |
| A04758 | 33513761 | Metabolites | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A04797 | 33503878 | Nutrients | Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. | 2021 | Details |
| A04814 | 33497019 | Liver Int | Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. | 2021 | Details |
| A04839 | 33488526 | Front Endocrinol (Lausanne) | Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. | 2021 | Details |
| A04853 | 33482185 | Life Sci | Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. | 2021 | Details |
| A04894 | 33464677 | Diabetes Obes Metab | Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. | 2021 | Details |
| A04924 | 33447122 | Clin Med Insights Endocrinol Diabetes | Oral GLP1 Analog: Where Does the Tide Go? | 2020 | Details |
| A04993 | 33421947 | EBioMedicine | A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. | 2021 | Details |
| A05041 | 33397230 | Curr Pharm Des | Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. | 2021 | Details |
| A05156 | 33352183 | Eur J Pharmacol | The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A05215 | 33336025 | Open Med (Wars) | Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet. | 2020 | Details |
| A05222 | 33333850 | J Clin Med | The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05230 | 33330497 | Front Cell Dev Biol | Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. | 2020 | Details |
| A05249 | 33324348 | Front Endocrinol (Lausanne) | Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. | 2020 | Details |
| A05386 | 33275161 | Diabetologia | The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels. | 2020 | Details |
| A05535 | 33216087 | Food Funct | Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. | 2020 | Details |
| A05624 | 33185364 | N Engl J Med | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A05637 | 33179890 | Am Fam Physician | Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management. | 2020 | Details |
| A05676 | 33163950 | JHEP Rep | NAFLD and liver transplantation: Disease burden, current management and future challenges. | 2020 | Details |
| A05677 | 33163832 | Hepatol Commun | Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. | 2020 | Details |
| A05843 | 33102775 | JGH Open | Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. | 2020 | Details |